Full history for every metric is available with a Kvantra account
YS Biopharma Co., Ltd. (YS)
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 257 | 503 | 687 | 573 | 615 | 577 |
| Operating profit | CNY m | -86 | - | |||||
| Net profit | CNY m | - | -192 | -1 | -145 | -433 | -100 | -436 |
| EPS reported | CNY | -0.94 | -4.54 | |||||
| Operating cashflow per share | CNY | -1.13 | -1.13 | |||||
| Capex per share | CNY | 0.17 | 0.17 | |||||
| FCF per share | CNY | -1.30 | -1.30 | |||||
| Free cash flow | CNY m | -139 | 0 | |||||
| Net debt | CNY m | 386 | 386 | |||||
| Book value equity | CNY m | 500 | 500 | |||||
| Book value per share | CNY | 4.67 | 5.00 | |||||
| Number of shares | m | 106.92 | 99.99 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.11 | 2.58 | |||||
| P/S LTM | x | 0.90 | 2.23 | |||||
| P/FCF LTM | x | -4.00 | -9.28 | |||||
| EV/EBITDA LTM | x | -19.39 | -5.33 | |||||
| EV/Sales LTM | x | 1.53 | 2.90 | |||||
| Earnings Yield LTM | % | -18.02% | -13.67% | |||||
| FCF Yield | % | -25.03% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -20.01% | -18.43% | |||||
| ROIC | % | -9.15% | -9.15% | |||||
| Operating margin | % | -14.03% | -14.03% | |||||
| Gross margin | % | 82.47% | 82.47% | |||||
| FCF/Sales | % | -22.58% | -22.58% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +7.24% | -16.56% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.34 | 0.00 | |||||
| Net Debt/EBITDA | x | -7.96 | -7.96 | |||||
| EBIT/Net interest | x | -5.48 | -5.48 | |||||
| Net debt/market cap | % | 69.56% | 29.96% | |||||
| Net debt/Equity | x | 0.77 | 0.77 | |||||
| Gross debt/equity | x | 0.83 | 0.83 | |||||
Company overview
YS Biopharma Co., Ltd., a biopharmaceutical firm established in Beijing, China, in 2002, specializes in the discovery, development, production, and commercialization of vaccines and therapeutic biologics. Their primary focus is on addressing infectious diseases and cancer. Central to their efforts is a proprietary PIKA immunomodulating technology platform, which supports the creation of preventive and therapeutic biologics for conditions such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. The company extends its operations across multiple countries, including China, the United States, Singapore, the United Arab Emirates, and the Philippines.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
YS Biopharma Co., Ltd. (YS)
YS Biopharma Co., Ltd., a biopharmaceutical firm established in Beijing, China, in 2002, specializes in the discovery, development, production, and commercialization of vaccines and therapeutic biologics. Their primary focus is on addressing infectious diseases and cancer. Central to their efforts is a proprietary PIKA immunomodulating technology platform, which supports the creation of preventive and therapeutic biologics for conditions such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. The company extends its operations across multiple countries, including China, the United States, Singapore, the United Arab Emirates, and the Philippines.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free